2. Academic Validation
  3. Chemokine CXCL14; a double-edged sword in cancer development

Chemokine CXCL14; a double-edged sword in cancer development

  • Int Immunopharmacol. 2021 Aug;97:107681. doi: 10.1016/j.intimp.2021.107681.
Arezoo Gowhari Shabgah 1,  Zahraa Haleem Al-Qaim 2,  Alexander Markov 3,  Alexei Valerievich Yumashev 4,  Fatemeh Ezzatifar 5,  Majid Ahmadi 6,  Seyed Mohammad Gheibihayat 7,  Jamshid Gholizadeh Navashenaq 8
Affiliations

Affiliations

  • 1 School of Medicine, Bam University of Medical Sciences, Bam, Iran.
  • 2 Al-Mustaqbal University College, Babylon, Hilla, Iraq.
  • 3 Tyumen State Medical University, Tyumen, Russian Federation.
  • 4 Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • 5 Molecular and Cell Biology Research Center, Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • 6 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • 7 Department of Biotechnology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • 8 Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran. Electronic address: [email protected].
PMID: 33932697 DOI: 10.1016/j.intimp.2021.107681
Abstract

Cancer is a leading cause of death worldwide and imposes a substantial financial burden. Therefore, it is essential to develop cost-effective approaches to inhibit tumor growth and development. The imbalance of cytokines and chemokines play an important role among different mechanisms involved in Cancer development. One of the strongly conserved chemokines that is constitutively expressed in skin epithelia is the chemokine CXCL14. As a member of the CXC subfamily of chemokines, CXCL14 is responsible for the infiltration of immune cells, maturation of dendritic cells, upregulation of major histocompatibility complex (MHC)-I expression, and cell mobilization. Moreover, dysregulation of CXCL14 in several cancers has been identified by several studies. Depending on the type or origin of the tumor and components of the tumor microenvironment, CXCL14 plays a conflicting role in Cancer. Although fibroblast-derived CXCL14 has a tumor-supportive role, epithelial-derived CXCL14 mainly inhibits tumor progression. Hence, this review will elucidate what is known on the mechanisms of CXCL14 and its therapeutic approaches in tumor treatment. CXCL14 is a promising approach for Cancer Immunotherapy.

Keywords

CXCL14; Cancer; Cancer-associated fibroblasts, biomarker; Chemokine dysregulation.

Figures
Products